A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03738397 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

673

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

BIOLOGICAL: Upadacitinib
BIOLOGICAL: Dupilumab
DRUG: Placebo to dupilumab
DRUG: Placebo to upadacitinib

Sponsor

AbbVie